Hong Kong strife holds up almost $100M of BioNTech's Series B haul
Late on Monday, it was revealed that German cancer drug developer BioNTech is eyeing a $100 million public listing in the United States, two months after the cancer-focused company unveiled a herculean $325 million in an upsized round of financing.
In the IPO filing, however, the Mainz-based drug developer revealed that shares worth about $97 million that were expected to be bought by an undisclosed Hong Kong-based investor have been delayed, in part due to the political unrest in Hong Kong and the ongoing trade dispute between the United States and China.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.